Figure 3. Induction of complement-dependent cytotoxicity (CDC) by biosimilar 1B8 mAb. (A) Human Burkitt’s lymphoma Daudi, Ramos and Raji cells were treated with 1 µg/mL of biosimilar 1B8 mAb for 2 h at 37°C. Human AB serum was used at 20%. Cell lysis was determined by PI uptake. (B) Dose-dependence for the induction of CDC by biosimilar 1B8 mAb on Ramos cells. Rituximab and isotype-matched chimeric C5 antibody were used as positive and negative controls, respectively. Results are representative of three independent experiments. ABS-human AB serum